The publisher explores UCB’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (27 July 2020)
Model updates (20 May 2020)
Model updates (20 February 2020)
Model updates (25 July 2019)
Snapshot
- Overview: UCB will experience impressive growth of its core portfolio of CNS and I&I products through 2021, but patent expiries will cause growth to slow over the long term.
- Key themes: [1] UCB will see solid near-term revenue growth due to its strong immunology and neurology assets [2] UCB saw several positive readouts from the Phase III program for bimekizumab in late 2019 that bode well for future uptake of the product [3] Growth from pipeline products – bimekizumab, zilucoplan, and rozanolixizumab – and recently launched Nayzilam and Evenity will see UCB increase revenues over the forecast period [4] UCB has several sizable brands with upcoming loss of exclusivity: Vimpat in 2022, Cimzia in 2024, and Briviact in 2026.
Model updates (27 July 2020)
- Bimekizumab forecast adjusted higher due to recent clinical trial results showing superiority to current standard-of-care
- Zilucoplan forecast added after closing of Ra Pharma acquisition
- Padsevonil forecast removed after UCB formally suspends program.
Model updates (20 May 2020)
- Padsevonil forecast lowered due to disappointing results from the Phase IIb ARISE trial.
Model updates (20 February 2020)
- Cimzia forecast adjusted higher
- Evenity forecast adjusted in 5EU and RoW to reflect approval and launch in first half of 2020
- Bimekizumab forecast adjusted higher due to strong results from three Phase III trials – BE VIVID, BE READY, and BE SURE.
Model updates (25 July 2019)
- Cimzia forecast adjusted higher due to growth in new patient populations, such as women of childbearing age and people living with psoriasis
- Vimpat forecast adjusted higher due to market share gains in all regions
- Briviact forecast adjusted higher due to continued growth in all regions
- Evenity launch in Europe delayed due to negative CHMP opinion and UCB appeal
- Nayzilam forecast added
- Padsevonil forecast added
- Rozanolixizumab forecast added.
Table of Contents
Company Background
Company Forecast
Company Profile
Clinical Trial Overview
